Founded in 1999 with a vision to secure Nepal’s healthcare needs, Quest Pharmaceuticals P. Ltd. helps millions lead healthier lives. Today, we are among the country’s most respected and trusted pharmaceutical manufacturers, safeguarding people’s lives through the formulation of science-based innovative medications.
- 1999
Establishment of Quest Pharmaceuticals P. Ltd.
Founded by four individuals with a vision to secure Nepal’s healthcare needs.
- 2001
Inauguration of Formal Operations
Began formal operations with 50 employees and fully functional Production, Quality Control, Quality Assurance, Regulatory and Marketing divisions.
Launched the company’s first molecule in cardiac segment - MYLOD (Amlodipine Besylate).
- 2004
WHO-GMP Certification
Awarded Good Manufacturing Practices (GMP) certification by the World Health Organization (WHO).
- 2005
R & D Division Establishment
Established the Research & Development division to enhance application of science-based innovative approaches to understand diseases better and formulate more effective molecules.
- 2007
Soft Gelatin Capsule formulation in Nepal
Pioneered production of soft gelatin capsules in Nepal with Vitamin-E product under the brand name EVA.
- 2010
Human Resource milestone
Company's workforce reaches 200-employees’ milestone.
- 2011
FNCCI ‘People Developer Certificate’
Awarded ‘People Developer Certificate’ under the People Excellence model in Large-Scale Industry category by the Federation of Nepalese Chambers of Commerce and Industries (FNCCI).
- 2012
Bioequivalence Confirmed
Performed bioequivalence study on our product, Clopid, as per internationally-accepted criteria and standards, and proved it to be bioequivalent with the generic drug, Clopidogrel.
- 2013
Bilayered Tablet Technology launched
Introduced bilayered tablet technology in two products – Telsartan AM and Metfor G1/G2.
- 2014
FNCCI ‘National Excellence Award’
Awarded ‘National Excellence Award’ in Medium-Scale Industry category by the Federation of Nepalese Chambers of Commerce and Industries (FNCCI).
- 2016
Telsartan AM launched in Nepal
Developed and launched Telsartan AM (Telmisartan 40 mg + Amlodipine 5 mg) - an uncoated bilayer tablet to treat hypertension for the first time in Nepal.
- 2017
Production Facility Upgraded & New Products launched
Upgraded the Production facility with the latest pharmaceutical technology to improve supply of life-saving medications.
Developed and launched Solay (Solifenacin 5 mg) – a film-coated tablet for treatment of hyperactive bladder for the first time in Nepal.
Launched US FDA approved molecule - Bentin (Butenafine Hydrochloride 1% w/w cream) used in treating dermal infections and DART (Dutasteride 0.5mg tablet) to help patients with prostate related problems.